Cancer Biomarkers Market

Cancer Biomarkers Market Size (2022 to 2027)

The global cancer biomarkers market size is estimated to be worth USD 30.74 billion by 2028 from USD 17.79 billion in 2023, registering a CAGR of 11.56% from 2023 to 2028.

Cancer Biomarkers Market Share Insights:

• Based on diseases, the prostate cancer disease segment held the largest share of the global cancer biomarkers market in 2022.
• Based on services, the sample preparation service segment captured a major share of the market in 2022.
• The North American market occupied the leading share of the global market in 2022.
• The Asia Pacific market held a considerable share of the worldwide market in 2022 and is predicted to grow at the fastest CAGR during the forecast period.

Impact of COVID-19 on the global cancer biomarkers market:

Biomarkers are chemical, physical, or biological parameters that can be used to specify disease states. Oncology biomarker testing offers high-speed, non-invasive cancer diagnosis and deem to improve cancer detection and screening. As a result, the global cancer biomarkers market is consolidated in nature at the top. Biomarkers are proteins or other substances released by cancer cells themselves or other cells in the body as a response to the cancer cells. Both benign and active cancer cells can release such markers. Detecting these markers can help the healthcare provider understand the nature and severity of cancer and choose a suitable treatment procedure for the patient. Individuals have different responses to cancer and require individual treatment regimes, leading to demand for biomarkers testing. Biomarkers are also called tumor markers and can detect both blood cancers and solid tumors. Biomarker testing can also be called somatic, molecular, genomic, and others. 

The pandemic severely impacted several markets and led to an economic crisis worldwide. Some of the most disturbed industries during the pandemic were the healthcare department. The rapid influx of patients and the shift toward covid assistance led to several other operations on hold, including cancer diagnosis and treatments. The lack of resources and healthcare professionals led to panic and disarray among hospitals. In addition, diagnostic procedures like cancer biomarkers were negatively impacted due to the pandemic as the research and development of cancer biomarkers were halted, and all non-urgent health procedures were postponed. However, the risk of cancer patients contracting covid and having a higher risk due to the virus led to more awareness of cancer diagnostics and biomarkers. In addition, the immunodeficiency of cancer patients, as they often lack proper immune response, meant more risk for covid. Therefore, even though the market had a negative impact on the market, there was a rise in the awareness surrounding cancer biomarkers. 

MARKET DRIVERS:

Technological advancements, rising healthcare spending, and the growing need for personalized medicine are primarily driving growth in the global cancer biomarkers market.

Increased focus on developing innovative products with the latest technology and the rising prevalence of minimally invasive or non-invasive surgeries worldwide accelerates the global cancer biomarkers market growth. In addition, increasing spending on healthcare, especially in urban areas, is another factor significantly expanding the market. 

Additionally, increasing knowledge of the utilization of biomarkers in the biotechnology field and a rise in the number of patients with various cancer diseases support the cancer biomarkers market growth. Cancer biomarkers have an immense role in diagnosing cancer diseases. It is entirely appropriate for screening and detecting cancer cells in various parts of the body, significantly influencing the growth rate of this market. Growing support from the government through investments is ascribed to bolstering the market growth.

The growing cases of cancer worldwide also lead to demand for the market. According to WHO reports, around 10 million cancer death cases were reported in 2020, meaning nearly one in every six persons had died of cancer. Therefore, the need for early cancer diagnosis is very eminent as it allows for appropriate early-stage treatment, giving the patient more chances of survival. In addition, the growing research and developments in the biomarkers field also support the market's growth. Some biomarker testing can be used to study new cancer treatments and record their efficiency, like a clinical trial. Additionally, biomarker testing is a precision testing methodology that allows for the development of personalized treatment regimes. Biomarker testing is available in different procedures for all types of cancers and patients like single biomarker testing, multigene biomarker testing, liquid biopsies, etc.; therefore, the wide range of options available to test the leads to more favorable treatment and research outcomes supporting the cancer biomarker market growth. 

MARKET RESTRAINTS:

However, fluctuations in the prices of the final products limit the market's growth rate. This equipment requires massive installation and maintenance, which also hinders the growth rate of the cancer biomarkers market. The need for more professionals to follow the procedures due to fewer training programs challenges market developers.

REPORT COVERAGE:

This research report on the global cancer biomarkers market has been segmented based on the disease, services, type, application, profiling technologies, and region.

Cancer Biomarkers Market - By Disease:

• Prostate Cancer
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Cervical Cancer
• Other Cancers

Based on disease, although every segment share goes simultaneously, the prostate cancer disease segment is leading with dominant market shares. Increasing awareness of the availability of treatment procedures among individuals is promoting the growth of this market.

The breast and lung cancer segments are also expected to grow significantly during the forecast period due to the growing cases of this cancer. For example, WHO reported 2.26 million cases of breast cancer and 2.21 million cases of lung cancer in 2020. The growing focus on EGFR and BRAF gene mutations for biomarker testing of small-cell lung cancers also supports the segment's growth. 

Cancer Biomarkers Market - By Services:

• Sample Preparation
• Assay Development
• Biomarkers Validation
• Testing

The sample preparation service type holds a prominent market share based on services. In addition, a rise in the construction activities of healthcare centers globally is ascribed to bolster the market's growth.

The biomarker testing segment is also expected to have grown during the forecast period due to the rising advancements in testing technologies and demand for early diagnosis and precision medicine. 

Cancer Biomarkers Market - By Application:

• Risk Assessment
• Development of Molecular Diagnostics
• Disease Diagnosis
• Drug Discovery & Development
• Drug Formulation

Based on the application, the Risk assessment application category has had the highest growth rate in the past few years with the demand for early diagnosis. Risk assessment is followed by the disease diagnosis segment, as it is essential to detect the stages of the disease and treatment pattern.

Due to the growing research and development in biomarkers, the drug discovery and development segment is also expected to grow during the forecast period.

Cancer Biomarkers Market - By Type:

• Protein Biomarkers
• Genetic Biomarkers
• Other Biomarkers

Based on type, the Protein biomarkers type holds a dominant share of the market. The growing priority for effective diagnosis of diseases to achieve better outcomes is lavishing the cancer biomarkers market's demand.

The genetic biomarkers segment is also expected to grow due to their efficiency and high usage rates, along with growing research in personalized medication based on DNA, RNA, etc., leading to the segment's growth. 

Cancer Biomarkers Market - By Profiling Technologies:

• Omics Technologies
  • Genomics
  • Proteomics
  • Metabolomics
  • Transcriptomics
  • Pharmacogenomics
• Imaging Technologies
• Immunoassays
• Cytogenetics
• Bioinformatics
• IVD Multivariate Index Assays

Based on profiling technologies, the omics technologies segment witnessed the largest share of the global market in 2022. However, the emergence of advanced technologies and the introduction of new devices that are simple and convenient for users are likely to outshine this market's growth.

Cancer Biomarkers Market - By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• The Middle East and Africa

The Asia-Pacific cancer biomarkers market is poised to record the highest growth rate in the forecast period. It is due to the supporting government funding for cancer biomarker research, increasing the prevalence of cancer. In addition, the rising demand for advanced healthcare facilities in developing economies such as India and China, a growing number of clinical trials, and the increasing focus of international players in emerging markets further help market growth in this region.

The North American cancer biomarkers market is expected to witness a promising CAGR during the forecast period due to the growing technological advancements in the healthcare sector, the rising R&D in cancer diagnostics and treatment, and the need for early diagnosis procedures drive market growth. In addition, the growing number of cancer cases in countries like the US, with around 1.9 million new cancer cases estimated to be diagnosed, also supports the market's growth. Furthermore, the growing disposable incomes and rising awareness regarding the advantages of early diagnosis also support the market's growth and the presence of essential market research in the region. 

The European cancer biomarkers market occupied a substantial share of the global market in 2021 and is expected to grow at a prominent CAGR during the forecast period.

The Latin American cancer biomarkers market is anticipated to grow steadily in the coming years.

The cancer biomarkers market in MEA is expected to occupy a moderate share of the worldwide market during the forecast period.

TOP COMPANIES IN THE CANCER BIOMARKERS MARKET:

Some of the major players operating in this market are Abbott Laboratories, Agendia Bv, Biocurex Inc, Biomerieux S.A., Biomoda Inc, Astellas Pharma Us Inc, Correlogic Systems Inc, Beckman Coulter Inc, Becton, Dickinson and Company, Clarient Inc, Diadexus Inc, Ambrilia Biopharma, Affymetrix Inc and Aureon Laboratories Inc.

Recent Developments:

• In February 2023, LiquidHALLMARK, a next-generation sequencing liquid biopsy test by Lucene, obtained a foundational Local Coverage Determination (LCD) from Palmetto GBA, a Medicare administrative contractor. 
• In February 2023, Shuttle Pharmaceuticals Holdings, Inc. agreed to lease a laboratory/office space in the Maryland biotech corridor. The company plans to expand its capabilities on predictive biomarkers through this acquisition. In addition, as the company is already known for improving the outcomes of cancer patients treated with radiation therapy (RT), the laboratory is expected to support its pipeline research and development. 
• In February 2023, Jounce Therapeutics, Inc. announced that it reduced its workforce by around 57%. The company is a clinical-stage research-based enterprise active in discovering and developing novel cancer immunotherapies and predictive biomarkers. The reduction of the workforce is due to the need for more funding in research and its plans to start new projects in partnership with different businesses.